NASDAQ:BYSI BeyondSpring (BYSI) Stock Price, News & Analysis $2.41 +0.12 (+5.24%) (As of 10/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About BeyondSpring Stock (NASDAQ:BYSI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BeyondSpring alerts:Sign Up Key Stats Today's Range$2.30▼$2.6050-Day Range$1.77▼$2.4152-Week Range$0.65▼$4.00Volume83,819 shsAverage Volume101,376 shsMarket Capitalization$94.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Read More… Shedding light on a dark secret (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Receive BYSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BeyondSpring and its competitors with MarketBeat's FREE daily newsletter. Email Address BYSI Stock News HeadlinesBeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024September 16, 2024 | globenewswire.comBeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024September 16, 2024 | globenewswire.comKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… October 2, 2024 | Paradigm Press (Ad)BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, PlinabulinSeptember 3, 2024 | globenewswire.comSEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology IndicationsAugust 6, 2024 | globenewswire.comBeyondSpring (NASDAQ:BYSI) shareholders have earned a 141% return over the last yearMay 22, 2024 | finance.yahoo.comBeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED TherapeuticsMay 16, 2024 | globenewswire.comBeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED TherapeuticsMay 3, 2024 | globenewswire.comSee More Headlines BYSI Stock Analysis - Frequently Asked Questions How have BYSI shares performed this year? BeyondSpring's stock was trading at $0.90 at the beginning of 2024. Since then, BYSI stock has increased by 167.8% and is now trading at $2.41. View the best growth stocks for 2024 here. How were BeyondSpring's earnings last quarter? BeyondSpring Inc. (NASDAQ:BYSI) posted its quarterly earnings results on Wednesday, December, 29th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.58) by $0.11. The business earned $0.34 million during the quarter, compared to analysts' expectations of $0.34 million. When did BeyondSpring IPO? BeyondSpring (BYSI) raised $4 million in an initial public offering (IPO) on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) acted as the underwriter for the IPO. How do I buy shares of BeyondSpring? Shares of BYSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BeyondSpring own? Based on aggregate information from My MarketBeat watchlists, some other companies that BeyondSpring investors own include Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ) and Pfizer (PFE). Company Calendar Last Earnings12/29/2021Today10/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BYSI CUSIPN/A CIK1677940 Webwww.beyondspringpharma.com Phone(646) 305-6387Fax1-646-882-4228Employees80Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.82 Quick Ratio2.31 Sales & Book Value Annual Sales$1.88 million Price / Sales50.14 Cash FlowN/A Price / Cash FlowN/A Book Value($0.91) per share Price / Book-2.65Miscellaneous Outstanding Shares39,029,000Free Float27,590,000Market Cap$94.06 million OptionableOptionable Beta0.26 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:BYSI) was last updated on 10/2/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredThey laughed when he picked Nvidia in 2016…Everyone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredFor Elon, I fear the worst is yet to come…Early last year I predicted that there would be a war on Elon Musk. This hateful rhetoric has led to two s...Porter & Company | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeyondSpring Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BeyondSpring With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.